Diatheva-Avitech APU

Diatheva is an Italian biotechnology company focused on the research, development, and manufacture of innovative biologics for oncology, infectious diseases, and personalized medicine. The company operates as both a product developer with a proprietary pipeline and a Contract Development and Manufacturing Organization (CDMO) specializing in recombinant proteins and monoclonal antibodies. Their lead candidate is an HIV-1 Tat-based vaccine aimed at therapeutic intervention for HIV-infected individuals. Diatheva leverages its GMP-certified facility to provide end-to-end services from early-stage research to clinical trial material production. The company is a member of the Solasia Pharma group and maintains strong ties with academic institutions to drive its innovation pipeline.